AKRO News and Press, Akero Therapeutics Inc. From 03/08/24

SOUTH SAN FRANCISCO, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its...

As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable to that of EFX alone and led to statistically significant improvements in non-invasive markers of liver injury and fibrosis and of metabolic health Results indi...

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...

2024-03-06 03:34:48 ET More on Akero Therapeutics Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program Akero stock jumps as lead drug shows added fibrosis improvement in MASH patients Eli Lilly hurts NASH drug developers after mid-stage win for obesity ...

2024-03-04 07:22:02 ET DENVER, Colo., Mar 04, 2024 ( 247marketnews.com )- Akero Therapeutics, Inc. (NASDAQ: AKRO ) released, this morning, its preliminary topline week 96 results from HARMONY, a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxife...

50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%) 50mg (36%, p<0.01) and 28mg (31%, p<0.01) EFX groups demonstrated ≥2 stage improve...

SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, will hold an investor conference on Monday, March 4 at 8:00 a.m. ET to share results...

SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year finan...

2024-02-12 15:06:51 ET More on CymaBay, Gilead, etc. Gilead Sciences: Cheap For A Reason Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript Gilead Sciences, Inc. 2023 Q4 - Results - Earnings Call Presentation Gilead to acquire CymaBay for $32.50/sh...

2024-02-06 12:58:10 ET More on Akero Therapeutics, 89bio, etc. Biotech And Pharma Diversification Pays Off Sagimet: Additional Upside Possible After Latest NASH Data Release Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play Karuna’s KarXT ...